Table of Content

08 September 2018, Volume 45 Issue 9 Previous Issue    Next Issue

For Selected:

Download Citations EndNote Reference Manager ProCite BibTeX RefWorks

Toggle Thumbnails

Effect of oxaliplatin induced autophagy on drug resistance of SGC7901 gastric cancer cells Wang Gang, Wang Huangzhen, Xue Ting 2018, 45 (8):  513-518.  doi: 10.3760/cma.j.issn.1673-422X.2018.09.001 Abstract ( 415 )   PDF (1301KB) ( 586 )   Save ObjectiveTo evaluate the effect of oxaliplatin induced autophagy on drug resistance of gastric cancer cells. MethodsGastric cancer SGC7901 cells were cultured in vitro and treated with different concentrations of oxaliplatin. Control group (oxaliplatin 0 μmol/L), oxaliplatin treatment groups (oxaliplatin 1, 2, 4 μmol/L) and oxaliplatin combined with doxorubicin groups (oxaliplatin 0, 1, 2, 4 μmol/L + doxorubicin 4 μmol/L) were set up. Cells were treated with different conditions for 24 hours. Western blotting and flow cytometry were used to detect the expression of autophagyrelated molecule Beclin1. Methyl thiazolyl tetrazolium (MTT) assay was used to detect the cell viability. Flow cytometry was used to analyze the uptake of doxorubicin in SGC7901 cells. ResultsThe expression of Beclin1 increased in gastric cancer cells treated with oxaliplatin. The percentages of positive cells treated with 1, 2 and 4 μmol/L oxaliplatin were respectively (9.51±0.27)%, (13.73±0.80)% and (20.17±1.03)%, control group was (2.17±0.15)%, and the difference was statistically significant (F=111.10, P<0.001). Compared with the control group, Beclin1 expression significantly increased in each treatment group (P<0.05; P<0.001; P<0.001). Different concentrations of 1, 2, 4 μmol/L oxaliplatin combined with doxorubicin were used to treat gastric cancer SGC7901 cells, fluorescence intensities of doxorubicin were 11 567±802, 13 433±808, 15 967±472, control group was 10 257±367, and the difference was statistically significant (F=79.81, P<0.001). Compared with the control group, the fluorescence intensity of doxorubicin significantly increased in each treatment group (P＜0.05; P<0.001; P<0.001). After treatment with oxaliplatin (1, 2, 4 μmol/L) and doxorubicin (4 μmol/L) for 24 hours, the cell viability levels were (68.27±1.64)%, (51.72±1.93)%, (39.60±1.80)% respectively. The cell viability levels of oxaliplatin treated with 1, 2 and 4 μmol/L were respectively (93.70±1.15)%, (76.53±1.10)%, (74.00±1.65)%. Compared with oxaliplatin alone, oxaliplatin combined with doxorubicin decreased cell viability more obviously, and the differences were statistically significant (t=8.91, P<0.001; t=9.21, P<0.001; t=10.34，P<0.001). The doxorubicin fluorescence intensity of oxaliplatin (2 μmol/L) combined with doxorubicin (4 μmol/L) group with pretreatment of autophagy inhibitor was 16 898±105, oxaliplatin combined with doxorubicin group was 22 245±168, and doxorubicin alone group was 17 562±67, and the difference was statistically significant (F=92.16, P<0.001). Compared with the pretreatment group, the doxorubicin fluorescence intensity of oxaliplatin combined with doxorubicin group was significantly increased (P<0.001). On the other hand, the cell viability levels of the above three groups were (81.33±3.54)%, (65.00±2.61)% and (101.02±3.58)%, and the difference was statistically significant (F=90.66, P<0.001). Compared with the pretreatment group, the cell viability level of oxaliplatin combined with doxorubicin group was significantly lower (P<0.001). ConclusionOxaliplatin can reduce the resistance of gastric cancer cells to chemotherapeutics by increasing the level of autophagy in gastric cancer cells, and improve the therapeutic effect of chemotherapy drugs. References | Related Articles | Metrics

Network pharmacology based study on mechanism of peony leaf in the treatment of cervical cancer Du Jingquan*, Guo Xiaoling, Wei Yongli, Li Keming, Yu Hao 2018, 45 (8):  519-524.  doi: 10.3760/cma.j.issn.1673-422X.2018.09.002 Abstract ( 464 )   PDF (2900KB) ( 702 )   Save ObjectiveTo analyze the multicomponent, multitarget and multipathway mechanism of peony leaf in the treatment of cervical cancer based on network pharmacology. MethodsThe possible active components and targets in peony leaf were screened and predicted by pharmacological database and analysis platform of traditional Chinese medicine system, and the related targets of cervical cancer diseases were obtained by searching Therapeutic Target Database and others. The potential targets for the disease regulation were screened according to the active components of peony leaves entering blood, then the key target names and the pathways involved in the treatment of peony leaf were selected according to the network topological characteristic parameters. Then, the enrichment analysis was carried out by using ClueGO software plugin. ResultsThere were 194 target sites for 11 blood entry components in peony leaves. Finally, 171 signal pathways were obtained, and 21 key pathways related to cervical cancer were obtained after the wide pathway was excluded, such as estrogen signaling pathway, neurotrophin signaling pathway and so on. ConclusionPeony leaves may play a vital role in the treatment of cervical cancer by acting on inflammatory, metabolic, immunological, endocrine and cell cycle related protein targets and pathways. References | Related Articles | Metrics

Clinical significance of miR-210 expression in breast cancer tissues and its influence on malignant behavior of triple negative breast cancer cells Liu Wenbin, Gao Nina 2018, 45 (8):  525-530.  doi: 10.3760/cma.j.issn.1673-422X.2018.09.003 Abstract ( 636 )   PDF (1143KB) ( 690 )   Save ObjectiveTo investigate the expression and clinical significance of microRNA210 (miR210) in breast cancer tissues, and to investigate its effect on the proliferation and metastasis of human triple negative breast cancer cell line MDAMB231 in vitro. MethodsThe breast cancer tissues and paracancerous tissues in 82 patients were collected in the Department of Pathology of Hunan Cancer Hospital  from December 2013 to September 2015. Quantitative realtime polymerase chain reaction (qRTPCR) technique was used to detect the expression level of miR210 in tissues and cells. The relationship between the expression of miR210 and clinical data and prognosis of patients were analyzed. The triple negative breast cancer cell line MDAMB231 transfected with fulllength miR210 plasmid was regarded as test group, and the cell transfected with blank vector was regarded as control group. CCK8 assay was used to detect the proliferation ability of cells in both groups. Transwell invasion and migration assays were used to detect the metastasis and invasion ability of  cells. ResultsThe results of qRTPCR showed that the expression level of miR210 was 0.198±0.014 in breast cancer tissues, which was significantly higher than that in paracancerous tissues (0.084±0.009), and the difference was statistically significant (t=8.141, P＜0.001). The expression level of miR210 in triple negative breast cancer tissues was 0.254±0.026, which was significantly higher than that in nontriple negative breast cancer tissues (0.167±0.015), and the difference was statistically significant (t=3.175, P=0.003). There were significant differences in TNM staging and molecular typing between the patients with high and low expression of miR210 (χ2=7.859, P=0.005; χ2=7.053, P=0.008). The 4year survival rate of patients with high expression of miR210 was significantly lower than that of patients with low expression of miR210 (49.37% vs. 76.80%), and the difference was statistically significant (χ2=4.743, P=0.024). The results of qRTPCR showed that the expression of miR210 in cells in test group was 0.517±0.038, which was significantly higher than that in control group (0.284±0.022), and the difference was statistically significant (t=9.280, P＜0.001). The results of CCK8 assay showed that the proliferation abilities of the test group were significantly higher than those of the control group in 48, 72 and 96 h (3.771±0.452 vs. 3.206±0.314; 7.662±0.619 vs. 6.736±0.552; 15.477±1.425 vs. 11.592±1.243), and the differences were statistically significant (t=2.296, P=0.025; t=2.496, P=0.019; t=4.594, P=0.001). The results of Transwell invasion assay showed that the cell number of test group in inferior surface was 107.8±13.0, which was significantly higher than that of control group (74.4±10.9), and the difference was statistically significant (t=3.732, P=0.001). The results of Transwell migration assay showed that the cell number of test group in inferior surface was 136.5±18.5, which was significantly higher than that of control group (87.4±15.7), and the difference was statistically significant (t=4.256, P＜0.001). ConclusionThe expression of miR210 in breast cancer tissues is high, and its expression is closely related to progression, malignancy and prognosis of patients. In vitro, miR210 can promote the malignant behavior of triple negative breast cancer cell line MDAMB231. It is a potential molecular marker and targeted treatment site. References | Related Articles | Metrics

Observation of the effect and safety assessment of lobaplatin for pleural lavage in the radical operation of NSCLC Wang Yang, Liang Yuepei, Li Mu, Zheng Min 2018, 45 (8):  531-534.  doi: 10.3760/cma.j.issn.1673-422X.2018.09.004 Abstract ( 1010 )   PDF (690KB) ( 498 )   Save ObjectiveTo evaluate the clinical efficacy and safety of lobaplatin for pleural lavage in the radical operation of nonsmall cell lung cancer (NSCLC). MethodsA total of 100 patients with NSCLC from June 2015 to December 2015 in Affiliated Hospital of Guilin Medical University were collected, and  were divided into experimental group and control group according to the patients′ or family′s wishes for treatment, with 50 cases in each group. The lobectomy and mediastinal lymph node dissection were performed for patients in the two groups. During the operation of the experimental group, we flushed the chest with 42 ℃ distilled water 2 000 ml first, then we washed and steeped the pleura with 500 ml of 5% glucose injection containing 50 mg lobaplatin for 10 min, in the end sucked out the washing fluid. During the operation, patients of the control group only received a treatment of same amount of distilled water. Then, the short and longterm effects and adverse reaction were tracked and compared. ResultsThe thoracic drainage of the first 3 days after operation in experimental group was (1 150±150) ml, and the control group was (790±110) ml, with a significant difference (t=3.352, P=0.029). The numbers of white blood cell ［(12.5±1.2)×109/L vs. (12.8±1.0)×109/L; t=0.333, P=0.756］, the platelets ［(235.2±52.5)×109/L vs. (236.5±34.5)］×109/L; t=0.036, P=0.973］, the creatinine ［(74.2±9.1) μmol/L vs. (75.2±8.7) μmol/L; t=0.138, P=0.897］, urea nitrogen ［(4.8±2.1) mmol/L vs. (5.5±2.4) mmol/L; t=0.391, P=0.716］, glutamicoxalacetic transaminase ［(9.6±3.8) U/L vs. (8.2±2.5) U/L; t=0.533, P=0.622］ and glutamicpyruvic transaminase ［(22.4±9.2) U/L vs. (21.8±6.4) U/L; t=0.093, P=0.931］ showed no significant differences between experimental group and control group. The positive rate of drainage exfoliative cells (4.0% vs. 16.0%) and ipsilateral recurrence rate (0 vs. 30.0%) of experimental group were lower than those of control group, with significant differences (χ2=4.000, P=0.046; χ2=17.647, P＜0.001). There was no death in experimental group during the followup period, and 2 patients in control group died. The rates of adverse reactions such as incisional pain (16.0% vs. 12.0%), nausea (10.0% vs. 14.0%), vomiting (4.0% vs. 0) and diarrhea (4.0% vs. 0) showed no significant differences between experimental group and control group (χ2=0.332, P=0.564; χ2=0.379, P=0.538; χ2=0.510, P=0.475; χ2=0.510, P=0.475). ConclusionThe application of lobaplatin for pleural lavage in the radical operation of lung cancer is safe and effective, which can significantly reduce the rate of ipsilateral recurrence. References | Related Articles | Metrics

Effects of Kanglaite injection combined with NP chemotherapy for immune status, inflammatory factors and quality of life of patients with advanced NSCLC Li Chao, Chen Junhua, Wu Jing 2018, 45 (8):  535-538.  doi: 10.3760/cma.j.issn.1673-422X.2018.09.005 Abstract ( 617 )   PDF (690KB) ( 641 )   Save ObjectiveTo investigate the effect of Kanglaite injection combined with NP (navelbine + cisplatin) chemotherapy for immune status, inflammatory factors and quality of life of patients with advanced nonsmall cell lung cancer (NSCLC). MethodsA total of 106 patients with advanced NSCLC admitted to our hospital from June 2014 to January 2017 were  divided into control group and observation group according to admission even and odd numbers, and 53 cases in each group. The patients in control group received chemotherapy with NP regimen, and the patients in observation group received Kanglaite injection + NP regimen chemotherapy. The immune status, inflammatory factors and quality of life of the patients in the two groups were observed and compared statistically. ResultsAfter treatment, the immune indexes including CD3+ (62.64%±3.96% vs. 54.08%±7.19%), CD4+ (37.10%±5.09% vs. 29.22%±6.38%), CD4+/CD8+ (1.96±0.62 vs. 1.12±0.39) and natural kill cells (22.45%±5.92% vs. 16.37%±6.13%) of observation group were apparently higher than those of control group (t=7.592, P＜0.001; t=7.029, P＜0.001; t=8.349, P＜0.001; t=5.194, P＜0.001). After treatment, the levels of interleukin6 ［(80.56±10.27) ng/L vs. (102.87±14.58) ng/L］, tumor necrosis factorα ［(8.35±2.73) ng/L vs. (15.69±3.14) ng/L］, Creactive protein ［(9.18±2.38) mg/L vs. (13.84±2.92) mg/L］ of observation group were significantly lower than those of control group (t=9.107, P＜0.001; t=12.843, P＜0.001; t=9.006, P＜0.001). The improved condition of Karnofsky performance status score of observation group was significantly better than that of control group (Z=3.133, P=0.002). The effective rate of observation group was significantly higher than that of control group (58.49% vs. 35.85%), with significant difference (χ2=5.451, P=0.020). ConclusionThe efficacy of Kanglaite injection combined with NP regimen in the treatment of advanced NSCLC is positive, which can effectively improve the immune status of patients, reduce inflammatory reaction and improve quality of life. References | Related Articles | Metrics

Association between metabolic syndrome and colorectal carcinoma based on a casecontrol study Lian Ying, Wang Linping, Liang Jing, Tang Fang 2018, 45 (8):  539-543.  doi: 10.3760/cma.j.issn.1673-422X.2018.09.006 Abstract ( 492 )   PDF (688KB) ( 1349 )   Save ObjectiveTo evaluate the association between metabolic syndrome and colorectal carcinoma. MethodsA total of 900 patients with colorectal carcinoma  from 2013 to 2016 in Qianfoshan Hospital Affiliated to Shandong University were selected as the case group and 1 774 noncolorectal carcinoma participants from health management center as the control group. Logistic regression model was used to identify the relationship between metabolic syndrome and colorectal carcinoma. ResultsCompared with the controls (27.0%), metabolic syndrome was more prevalent among cases (35.4%). The difference was statistically significant (χ2=20.33, P<0.01). Multivariate logistic regression analyses showed that metabolic syndrome as an entity increased colorectal carcinoma risk (OR=1.38, 95%CI: 1.081.75, χ2=17.68, P＜0.01). Subjects with 2 and 3 or more components of the metabolic syndrome had an increased risk of colorectal carcinoma, and the ORs of colorectal carcinoma were 1.37 and 1.60, respectively. Genderspecific patterns were also observed in the association between metabolic syndrome, component and colorectal carcinoma (χ2=5.40, P=0.02; χ2=8.66, P<0.01). ConclusionMetabolic syndrome is associated with the occurrence of colorectal carcinoma. An increasing trend in risk of colorectal carcinoma with the number of metabolic syndrome components is observed. References | Related Articles | Metrics

Clinical study on simultaneous modulated accelerated radiotherapy for advanced cervical cancer Yang Chunhua, Wang Xia, Zhang Longzhen, Chen Jie, Tang Tianyou, Liu Guihong 2018, 45 (8):  544-547.  doi: 10.3760/cma.j.issn.1673-422X.2018.09.007 Abstract ( 715 )   PDF (681KB) ( 626 )   Save ObjectiveTo study the clinical efficiency and adverse reactions of simultaneous modulated accelerated radiotherapy (SMART) and intensitymodulated radiation therapy (IMRT) in advanced cervical cancer. MethodsSixty patients with advanced cervical cancer were collected from April 2011 to April 2017 in our hospital. The 60 patients were randomly divided into experimental group (30 cases) and control group (30 cases) by using stratified randomization method. The two groups were given intracavitary irradiation and concurrent chemotherapy. The patients in experimental group were treated with SMART and the patients in control group were treated with IMRT. 95% planned target volume was 50.4 Gy/28 F in the two groups and the dose for IMRT with simultaneous integrated boost was 64.4 Gy/28 F to the planning target volume. Disease progression, survival time and adverse reactions of the two groups were compared. ResultsAt the end of radiotherapy, the experimental group had 23 patients with complete response (CR), 4 patients with partial response (PR), 2 patients with unaltered stable disease (SD), 1 patient with progressive disease (PD), and the control group had 22 patients with CR, 3 patients with PR, 3 patients with SD, 2 patients with PD. The overall efficiency of the experimental group was slightly higher than that of the control group (90.0% vs. 83.3%), but the difference was not statistically significant (χ2=0.144, P=0.704). After 3 months of radiotherapy, the experimental group had 28 patients with CR, 1 patient with PR, 1 patient with PD, and the control group had 22 patients with CR, 2 patients with PR, 3 patients with SD, 3 patients with PD. The overall efficiency of the experimental group (96.7%) was higher than that of the control group (96.7% vs. 80.0%), but the difference was not statistically significant (χ2=2.588, P=0.108). The median overall survival time of the experimental group and control group were 43 months and 38 months, and the difference was statistically significant (χ2=7.087, P=0.008). The 1year survival rates of the two groups were 96.6% and 85.7%, and the 3year survival rates were 86.2% and 60.7%, respectively. There were no significant differences in the incidences of gastrointestinal reaction (66.7% vs. 63.3%, χ2=0.073, P=0.787), urinary system reaction (33.3% vs. 30.0%, χ2=0.077, P=0.781) and bone marrow suppression (83.3% vs. 86.7%, χ2=0.000, P=1.000) between the two groups. ConclusionThe efficiency of advanced cervical cancer patient treated with SMART is better than IMRT, and the adverse reactions are tolerable, which is worthy of clinical promotion. References | Related Articles | Metrics

Essential characteristics and functions of SLC25 family in tumor Cheng Siwei, Hu Jun, Xiong Wujun 2018, 45 (8):  548-551.  doi: 10.3760/cma.j.issn.1673-422X.2018.09.008 Abstract ( 2124 )   PDF (672KB) ( 1670 )   Save The solute carrier protein 25 family (SLC25) is one of superfamily in solute carrier protein family. The members of SLC25 family function by transporting various solutes across the mitochondrial membrane. Their substrates vary in property, molecular size and mode of transport, and they closely involve in numerous physiological functions. More and more researches indicate that some members of SLC25 family are abnormally expressed in tumors, and some of them play important roles in the occurrence and development of tumors. For example, some members participate in tumorigenesis by regulating cell metabolism, death and proliferation. References | Related Articles | Metrics

Progress of circulating tumor cells in clinical application Chen Luojun, Li Na, Tian Jingyuan, Song Qibin, Yu Jinming 2018, 45 (8):  552-555.  doi: 10.3760/cma.j.issn.1673-422X.2018.09.009 Abstract ( 497 )   PDF (676KB) ( 664 )   Save Circulating tumor cells (CTCs) are cancerous cells that shed from the primary tumor or metastases into the bloodstream. The currently clinical applicability of CTCs approved by the US Food and Drug Administration (FDA) is that CTCs can be prognostic biomarker for patients with metastatic breast cancer, prostate cancer and colorectal cancer. CTCs also have great potential in the prognosis assessment of other metastatic or localized tumors, as well as early screening of tumors, analysis of molecular profiling, guiding treatment decisions, and monitoring of treatment response. Currently, various studies are being carried out to further explore the clinical application of CTCs, and provide new strategies and new prospects for individualized and precise treatment of cancer patients. References | Related Articles | Metrics

CRISPR/Cas9 genome editing system and its application in tumor therapy Yang Yehuan, Yang Chengwei, Tan Xiaoqing, Gao Xingchun 2018, 45 (8):  556-560.  doi: 10.3760/cma.j.issn.1673-422X.2018.09.010 Abstract ( 1065 )   PDF (682KB) ( 1112 )   Save CRISPR/Cas9 gene editing system is a new tool of gene editing technology based on the immune mechanism of archaea against foreign nucleic acid invasion. Due to its high efficiency and accuracy, CRISPR/Cas9 genome editing technology has been widely used in tumor therapeutic research, such as targeted knockout of oncogenes, repair of tumor suppressor genes, breaking immune tolerance, and construction of tumor models, which brings revolutionary development to tumor gene therapy. References | Related Articles | Metrics

Clinical application of cisplatin and nedaplatin Qiao Yunfeng, Li Ping, Fu Zhenming 2018, 45 (8):  561-565.  doi: 10.3760/cma.j.issn.1673-422X.2018.09.011 Abstract ( 861 )   PDF (684KB) ( 1431 )   Save Cisplatin and nedaplatin have been proved to be effective for most of solid tumors including head and neck cancer, esophageal cancer, lung cancer, bladder cancer, ovary epithelial cancer, testicular cancer and cervical cancer. Nedaplatin is often used as an alternative to cisplatin in Asia. However, the evidence from phase Ⅲ clinical trials is insufficient. Clinicians should be cautious when using nedaplatin to replace cisplatin. References | Related Articles | Metrics

Progress of radiomics and radiogenomics in lung cancer Guo Tianhui, Wang Haoming, Ren Ruimei, Xu Jinpeng, Song Hao, Xiao Wenjing, Xu Mingjin, Liu Xiguang 2018, 45 (8):  566-569.  doi: 10.3760/cma.j.issn.1673-422X.2018.09.012 Abstract ( 918 )   PDF (673KB) ( 1015 )   Save Radiomics and radiogenomics are used to provide comprehensive tumor biological characteristics and further clinical information by extracting, screening and analyzing the most valuable quantitative radiomics features. In recent years, numerous studies have shown that radiomics plays a role in the diagnosis, treatment and predicting efficacy and prognosis of lung cancer. Radiogenomics shows a great value in the prediction of lung cancer gene phenotype and individualized precision treatment by combining radiomics features with genomics, proteomics and so on. Radiomics and radiogenomics are noninvasive, quantitative, and reproducible, and they can provide multidirectional tumor biological characteristics, which are expected to be widely used in the precise medical treatment of lung cancer in the future. References | Related Articles | Metrics

Research progress of hypofractionated whole breast irradiation after breast conserving surgery Zheng Linjing, Dong Yinping, Hu Bing, Xia Chongsheng, Li Baosheng, Huang Wei 2018, 45 (8):  570-573.  doi: 10.3760/cma.j.issn.1673-422X.2018.09.013 Abstract ( 723 )   PDF (676KB) ( 582 )   Save Hypofractionated radiotherapy after breast conserving surgery has become a new standard treatment of early breast cancer. Clinical researches show that α/β value of breast cancer is lower than that of other tumors, and the breast cancer is more suitable for hypofractionated radiotherapy. Hypofractionated radiotherapy has good economic benefits, and longterm followup results from a number of classical randomized controlled studies have shown that hypofractionated whole breast irradiation is effective and safe. With the extensive application of hypofractionated irradiation, this technology has been gradually extended to regional nodal irradiation, postmastectomy radiotherapy and breast ductal carcinoma in situ. References | Related Articles | Metrics